Top-line Phase III data from the first pivotal trial of argenx SE’s lead product, efgartigimod, show it is associated with a fast onset of action, deep responses and the potential for sustained responses in patients with myasthenia gravis, and the European biotech is working on commercialization plans for the potential first-in-class product, with approvals expected in 2021.
Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study
US BLA Submission By End Of 2020
The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.

More from Clinical Trials
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
More from R&D
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.